AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03591679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 units by slow intravenous drip injection
Study NCT03591679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral uterine artery ligation
Description: • The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
Study NCT01203397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G
Description: APLIED 4 TIMES/DAY AT LESION
Study NCT01203397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G
Description: APLIED 4 TIMES/DAY AT LESION
Study NCT02824679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Description: 20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
Study NCT01469013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01469013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01469013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Study NCT02902432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
Study NCT01741974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Karinat
Study NCT01741974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Karinat 500 mg tablet
Study NCT04107129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Estradiol and Progesterone levels in the blood will be checked
Study NCT06278025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assessment
Description: DCF Muscle Strength Evaluation~DCF muscle strength was determined using the 5-step Craniocervical Flexion Test (CCFT) performed with a Chattanooga Stabilizer ™ Pressure Biofeedback Unit which was developed by Jull et al. \[33, 34\]. The CCFT is based on the craniocervical flexion movement, which is provided by DCF muscle contraction. The CCFT includes 5 pressure increments starting with 20mmHg.Activation score ranges from 0 to 10. The performance index is determined by both the highest pressure level and the number of repetitions.~Evaluation of the DCF Endurance The DCF endurance test, which is a valid and reliable method, was used to measure DCF muscle endurance \[36\]. Conducted in supine, endurance is measured by calculating the time (in seconds) an individual can raise their head at minimal flexion angle.
Study NCT01137266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS
Study NCT01191619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McIvor retractor
Description: The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
Study NCT05038072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprachoroidal injection of Triamcinolone Acetonide.
Description: 4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
Study NCT03552913 — intervention group
Intervention type: PROCEDURE
Intervention: One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
Description: One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
Study NCT03552913 — intervention group
Intervention type: PROCEDURE
Intervention: One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
Description: One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
Study NCT03552913 — intervention group
Intervention type: PROCEDURE
Intervention: No specific program toward improving practices
Description: No specific program toward improving practices
Study NCT02772653 — intervention group
Intervention type: OTHER
Intervention: Blood Lactate
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study NCT02772653 — intervention group
Intervention type: OTHER
Intervention: Blood Base Excess
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study NCT00588731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Active Cannabidiol daily over 6 weeks
Study NCT02772653 — intervention group
Intervention type: OTHER
Intervention: Blood B-type Natriuretic Peptide
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study NCT00588731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04197128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resorbable Collagen membrane with bone graft for augmentation
Description: Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)
Study NCT02772653 — intervention group
Intervention type: OTHER
Intervention: Blood Thromboelastometry (ROTEM)
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study NCT02772653 — intervention group
Intervention type: OTHER
Intervention: Near-infrared spectroscopy
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study NCT02772653 — intervention group
Intervention type: OTHER
Intervention: Sublingual videomicroscopy
Description: Analyzed at the 1rst, 8th and 24th hour from hospital admission
Study NCT00750750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray (MFNS)
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
Study NCT04197128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ribose cross linked collagen matrix for augmentation
Description: Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany).
Study NCT00750750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFNS
Description: Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
Study NCT00750750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
Study NCT00750750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Study NCT00624312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procrit
Description: 10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit
Study NCT00624312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo
Study NCT00762606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification cataract extraction surgery
Description: Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
Study NCT00762606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small incision cataract surgery
Description: Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
Study NCT01419730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU
Study NCT01419730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Progressive walking and resistance band exercise prescription for a period of 24 weeks
Study NCT01335165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1102
Description: Single Ascending Dose IV
Study NCT01335165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1103
Description: Single Ascending Dose IV or SC
Study NCT02939469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiologic maneuvers
Description: Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch
Study NCT03342872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Training: FBS System Mapping and MTFS-I Installation
Description: Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
Study NCT03342872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings
Description: Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
Study NCT00755781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Inhalation Solution (CIS)
Description: Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
Study NCT01909336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Saline in 3.3% dextrose
Description: Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
Study NCT01909336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.45% Saline in 5% dextrose
Description: Hypotonic Solutions: 0.45% Saline in 5% dextrose
Study NCT02997137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOT-01
Description: Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks
Study NCT02997137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks
Study NCT00778882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM106
Description: Autologous hematopoietic stem cells with MT-gp91 retroviral vector
Study NCT01961882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501
Study NCT01961882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02112279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor microbiota applied via colonoscopy.
Description: B. Preparation of donor sample 1. Instillation via Colonoscopy~1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe.
Study NCT01909336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline in 5% dextrose
Description: Isotonic Solutions 0.9% Saline in 5% dextrose
Study NCT01469013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy
Study NCT01469013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally as background therapy
Study NCT03085641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow oxygen therapy
Description: nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
Study NCT00862849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Study NCT00862849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Study NCT00862849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Study NCT01351766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
Study NCT00078962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV
Study NCT00078962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00078962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02466802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
Study NCT02466802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
Study NCT03692091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial Injection
Description: Injection in to subacromial space in the shoulder from anterior portal
Study NCT02000323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early enteral nutrition
Description: Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day
Study NCT02000323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified early enteral nutrition
Description: Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day.
Study NCT01805635 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01275560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole,per os,500mg, 3 per day during 10 days
Study NCT01275560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CArbosylane
Study NCT05398835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online interventions promoting HIV self-testing
Description: 1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
Study NCT02644798 — intervention group
Intervention type: OTHER
Intervention: Baseline-recorded data recorded
Description: Baseline-recorded data recorded. Peripheral blood samples were drawn.
Study NCT04212377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells for endometrial cancer
Description: Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
Study NCT02294448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
Study NCT03016741 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GnRH agonist/antagonist
Description: Given GnRH agonist/antagonist therapy
Study NCT03016741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Given by mouth
Study NCT03016741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Description: Given by mouth
Study NCT03016741 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: Given by mouth
Study NCT04189107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: High-dose dexamethasone peroperative and postoperative on day 2 and 4
Study NCT03785145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into the LCL.
Study NCT04189107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4